179 related articles for article (PubMed ID: 36670529)
1. A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas.
Muragaki Y; Ishikawa E; Maruyama T; Nitta M; Saito T; Ikuta S; Komori T; Kawamata T; Yamamoto T; Tsuboi K; Matsumura A; Nakamura H; Kuroda J; Abe T; Momii Y; Saito R; Tominaga T; Tabei Y; Suzuki I; Arakawa Y; Miyamoto S; Matsutani M; Karasawa K; Nakazato Y; Maebayashi K; Hashimoto K; Ohno T
J Neurosurg; 2023 Aug; 139(2):344-354. PubMed ID: 36670529
[TBL] [Abstract][Full Text] [Related]
2. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
3. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article.
Muragaki Y; Maruyama T; Iseki H; Tanaka M; Shinohara C; Takakura K; Tsuboi K; Yamamoto T; Matsumura A; Matsutani M; Karasawa K; Shimada K; Yamaguchi N; Nakazato Y; Sato K; Uemae Y; Ohno T; Okada Y; Hori T
J Neurosurg; 2011 Aug; 115(2):248-55. PubMed ID: 21568657
[TBL] [Abstract][Full Text] [Related]
4. Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
Sakamoto N; Ishikawa E; Yamamoto T; Satomi K; Nakai K; Sato M; Enomoto T; Morishita Y; Takano S; Ohno T; Tsuboi K; Matsumura A
Neurol Med Chir (Tokyo); 2011; 51(4):319-25. PubMed ID: 21515959
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial.
Cho DY; Yang WK; Lee HC; Hsu DM; Lin HL; Lin SZ; Chen CC; Harn HJ; Liu CL; Lee WY; Ho LH
World Neurosurg; 2012; 77(5-6):736-44. PubMed ID: 22120301
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients.
Ishikawa E; Tsuboi K; Yamamoto T; Muroi A; Takano S; Enomoto T; Matsumura A; Ohno T
Cancer Sci; 2007 Aug; 98(8):1226-33. PubMed ID: 17517052
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.
Wen PY; Reardon DA; Armstrong TS; Phuphanich S; Aiken RD; Landolfi JC; Curry WT; Zhu JJ; Glantz M; Peereboom DM; Markert JM; LaRocca R; O'Rourke DM; Fink K; Kim L; Gruber M; Lesser GJ; Pan E; Kesari S; Muzikansky A; Pinilla C; Santos RG; Yu JS
Clin Cancer Res; 2019 Oct; 25(19):5799-5807. PubMed ID: 31320597
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
11. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
12. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
Ardon H; Van Gool SW; Verschuere T; Maes W; Fieuws S; Sciot R; Wilms G; Demaerel P; Goffin J; Van Calenbergh F; Menten J; Clement P; Debiec-Rychter M; De Vleeschouwer S
Cancer Immunol Immunother; 2012 Nov; 61(11):2033-44. PubMed ID: 22527250
[TBL] [Abstract][Full Text] [Related]
13. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Butowski N; Chang SM; Lamborn KR; Polley MY; Pieper R; Costello JF; Vandenberg S; Parvataneni R; Nicole A; Sneed PK; Clarke J; Hsieh E; Costa BM; Reis RM; Hristova-Kazmierski M; Nicol SJ; Thornton DE; Prados MD
Neuro Oncol; 2011 Dec; 13(12):1331-8. PubMed ID: 21896554
[TBL] [Abstract][Full Text] [Related]
14. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
15. Results from a first-in-human phase I safety trial to evaluate the use of a vascularized pericranial/temporoparietal fascial flap to line the resection cavity following resection of newly diagnosed glioblastoma.
Doron O; Wong T; Ablyazova F; Singha S; Cavallaro J; Ben-Shalom N; D'Amico RS; Harshan M; McKeown A; Zlochower A; Langer DJ; Boockvar JA
J Neurooncol; 2024 Jun; 168(2):225-235. PubMed ID: 38664311
[TBL] [Abstract][Full Text] [Related]
16. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Liau LM; Ashkan K; Tran DD; Campian JL; Trusheim JE; Cobbs CS; Heth JA; Salacz M; Taylor S; D'Andre SD; Iwamoto FM; Dropcho EJ; Moshel YA; Walter KA; Pillainayagam CP; Aiken R; Chaudhary R; Goldlust SA; Bota DA; Duic P; Grewal J; Elinzano H; Toms SA; Lillehei KO; Mikkelsen T; Walbert T; Abram SR; Brenner AJ; Brem S; Ewend MG; Khagi S; Portnow J; Kim LJ; Loudon WG; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Lindhorst S; Lutzky J; Sloan AE; Schackert G; Krex D; Meisel HJ; Wu J; Davis RP; Duma C; Etame AB; Mathieu D; Kesari S; Piccioni D; Westphal M; Baskin DS; New PZ; Lacroix M; May SA; Pluard TJ; Tse V; Green RM; Villano JL; Pearlman M; Petrecca K; Schulder M; Taylor LP; Maida AE; Prins RM; Cloughesy TF; Mulholland P; Bosch ML
J Transl Med; 2018 May; 16(1):142. PubMed ID: 29843811
[TBL] [Abstract][Full Text] [Related]
17. Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.
Yao Y; Luo F; Tang C; Chen D; Qin Z; Hua W; Xu M; Zhong P; Yu S; Chen D; Ding X; Zhang Y; Zheng X; Yang J; Qian J; Deng Y; Hoon DSB; Hu J; Chu Y; Zhou L
Cancer Immunol Immunother; 2018 Nov; 67(11):1777-1788. PubMed ID: 30159779
[TBL] [Abstract][Full Text] [Related]
18. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Bota DA; Taylor TH; Piccioni DE; Duma CM; LaRocca RV; Kesari S; Carrillo JA; Abedi M; Aiken RD; Hsu FPK; Kong XT; Hsieh C; Bota PG; Nistor GI; Keirstead HS; Dillman RO
J Exp Clin Cancer Res; 2022 Dec; 41(1):344. PubMed ID: 36517865
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Brachman DG; Pugh SL; Ashby LS; Thomas TA; Dunbar EM; Narayan S; Robins HI; Bovi JA; Rockhill JK; Won M; Curran WP
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):961-7. PubMed ID: 25832688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
